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ABSTRACT
Background and objective: Intravenous (i.v.) antibio-
tics are needed for rescue when preventative therapy
fails to achieve stability among adults with cystic ﬁbro-
sis (CF). Understanding the distribution of i.v. days can
provide insight into the care that adults with CF need.
We aim to determine the baseline characteristics that
are associated with higher i.v. use, in particular to test
the hypothesis that prior-year i.v. use is associated with
future-year i.v. use.
Methods: This is a cross-sectional analysis of the
2013–2014 UK CF registry data. Stepwise logistic regres-
sion was performed using current-year i.v. days as the
dependent variable, and demographic variables includ-
ing prior-year i.v. days as the covariates. Based on these
results, study sample was divided into clinically mean-
ingful subgroups using analysis similar to tree-based
method.
Results: Data were available for 4269 adults in 2013 and
4644 adults in 2014. Prior-year i.v. use was the strongest
predictor for current-year i.v. use followed by forced
expiratory volume in 1 s (FEV1). Adults with high prior-
year i.v. use (>14 days) continued to require high levels
of i.v., regardless of FEV1. Those with high prior-year i.
v. use and FEV1 ≥70% had higher current-year i.v. days
compared to adults with low prior-year i.v. use and
FEV1 <40% (28 days, interquartile range (IQR):
11–41 days vs 14 days, IQR: 0–28 days; Mann–Whitney
P-value <0.001 in 2013).
Conclusion: CF people with prior high levels of rescue
often continue to need high levels of rescue even if they
have good FEV1. The reasons for this require further
investigations.
Key words: cystic ﬁbrosis, data interpretation, intravenous
antibiotic, registry analysis, pulmonary exacerbation.
Abbreviations: CF, cystic ﬁbrosis; CFRD, CF-related diabetes;
CFTR, CF transmembrane regulator; FEV1, forced expiratory
volume in 1 s; IQR, interquartile range; NHS, National Health
Service; PERT, pancreatic replacement therapy; US CFFPR, US
CF Foundation Patient Registry.
INTRODUCTION
Cystic ﬁbrosis (CF) is an autosomal recessive genetic
condition caused by mutations in the gene encoding
the CF transmembrane regulator (CFTR) that affects
around 10 000 people in the UK.1,2 CF is a multisystem
condition1 but lungs are the main organ affected, with
CFTR dysfunction causing abnormal airway surface liq-
uid.1,3 People with CF are particularly susceptible to
infection causing acute deterioration in lung health
(i.e. pulmonary exacerbations), which leads to progres-
sive lung damage and eventually respiratory failure.4
An important treatment option in CF is preventative
inhaled therapies consisting of mucolytics and antibio-
tics, which have proven efﬁcacy in reducing the fre-
quency of exacerbations.5,6 The effectiveness of these
treatments is however limited by a real-world medica-
tion adherence rates of 35–50%.7,8 Acute treatment of
pulmonary exacerbations has relatively limited research
evidence.9 However, the importance of intravenous (i.
v.) antibiotics in managing CF is indisputable—CF cen-
tres that use less antibiotics or have higher threshold
for initiating i.v. in the face of an exacerbation were
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SUMMARY AT A GLANCE
Intravenous (i.v.) antibiotic is an important treat-
ment option in cystic ﬁbrosis and is also a marker
of pulmonary exacerbations. Our study showed that
previous-year i.v. use is a strong predictor of
current-year i.v. use. This ﬁnding could help clini-
cians to identify people most at risk of future
exacerbation.
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associated with people having lower lung function.10,11
Indeed, i.v. antibiotics are recommended in all the
major CF guidelines to treat exacerbations.12–15
Understanding the clinical characteristics associated
with i.v. antibiotics use is clinically important as it can
provide insight into the care that people with CF need
and the resources that are required for CF care. Exacer-
bation is also an important end point in CF clinical
trials,16 and clinical factors associated with exacerbation
could have implications for trial design.
A recent US CF Foundation Patient Registry
(US CFFPR) data analysis has found that the frequency
of prior-year i.v.-treated exacerbations is strongly asso-
ciated with the frequency of future-year i.v.-treated
exacerbations,17 even after adjustment for the other
case-mix factors, for example lung function.17–19 We
analysed the 2013–2014 UK CF registry data to test
whether the hypothesis that prior-year i.v. use is asso-
ciated with future-year i.v. use, is also generalizable to
the UK CF population.
METHODS
This is a cross-sectional analysis using the UK CF regis-
try data for 2013–2014 from 28 UK adult CF centres.
National Health Service (NHS) research ethics approval
(Huntingdon Research Ethics Committee 07/Q0104/2)
was granted for the UK CF Registry. Under the terms of
the NHS ethics approval, the UK CF Trust steering
committee approved this study.
People with lung transplantation and those on ivacaftor
were excluded as both treatments have transformative
effects on health outcomes,20,21 such that their exacerba-
tion rates and forced expiratory volume in 1 s (FEV1) no
longer represent that of a typical adult with CF.
Data
The following data were obtained
• Demographics: age, gender, CF centre identiﬁer;
• Pancreatic status: people on pancreatic replacement
therapy (PERT) were considered ‘pancreatic insufﬁ-
cient’ while those not on PERT were considered
‘pancreatic sufﬁcient’;
• CF-related diabetes: present (as deﬁned by the UK
CF Trust guideline),22 or not present;
• Pseudomonas aeruginosa status: no P. aeruginosa
(negative cultures over a year), intermittent (positive
cultures not fulﬁlling deﬁnition of chronic) or
chronic (≥2 samples positive in one year);23
• Body mass index, BMI, in kg/m2;
• FEV1 during annual review (in % predicted, calcu-
lated with Knudson equation);24
• Annual total i.v. antibiotic days (in number of days).
Data were collected from people aged ≥16 years dur-
ing annual reviews from January 2013 to December
2014. Since prior-year i.v. use was a covariate in the
analysis, i.v. use data for 2012 were also obtained.
Number of days on i.v. antibiotic, instead of number
of i.v. courses, was chosen for analysis since it captures
information on the cumulative i.v. antibiotic exposure
to treat pulmonary exacerbations over a 1-year period
(not all i.v. courses are of the same duration).25
Statistical analysis
Analyses were performed using SPSS v22 (IBM Corp,
Armonk, NY, USA). Data for 2013 and 2014 were ana-
lysed separately to determine the consistency of any
observations. The analysis consisted of two stages.
First, logistic regression was performed to identify the
order of the strength of association between the demo-
graphic and clinical variables with the current-year i.v.
use. Based on these results, the study sample was
divided into clinically meaningful subgroups using
analysis similar to tree-based method26 for comparison
of current-year i.v. use between the subgroups.
Logistic regression was performed using current-year
i.v. days (≤14 days vs >14 days) as the dependent varia-
ble. 14-Day was selected as the cut-off since mean and
median duration of each i.v. course in 2013 and 2014
was 14 days. The duration of a ‘standard’ i.v. course to
treat an exacerbation is usually 14 days,12,15 and people
with ≥2 exacerbations per year (i.e. time between exac-
erbation <6 months17) have the most rapid FEV1
decline.27 Age, gender, CF centre (as a categorical vari-
able), pancreatic status, CF-related diabetes, intermit-
tent P. aeruginosa (yes/no), chronic P. aeruginosa
(yes/no), BMI, %FEV1 and prior-year i.v. days (as a
continuous variable) were the covariates. For this pro-
cedure, forward stepwise conditional analysis (proba-
bility for entry 0.05; probability for removal 0.10) was
performed in a binary logistic regression model. The
procedure began by identifying the covariate that was
most strongly associated with current-year i.v. use. The
next strongest associated covariate was then selected
after controlling for the ﬁrst covariate. This continued
until no further statistically signiﬁcant covariates can
be added to the model. Stepwise regression allows a
relatively parsimonious model to be built even when
several correlated covariates are present,28,29 but it is
essentially an exploratory analysis because it can lead
to inﬂated Type I errors.30,31
Therefore, the results from the stepwise logistic
regression were subjected to a further analysis similar
to tree-based method to test the hypothesis that prior-
year i.v. use is associated with future-year i.v. use.
Tree-based method is an efﬁcient approach to under-
stand the impact of risk factors for a condition where
many potential confounders exist.24 For this analysis,
the covariate most strongly associated with current-
year i.v. use as identiﬁed by stepwise logistic regression
was used for the ﬁrst ‘layer’ division of the study sam-
ple. Then, a further ‘layer’ of division for each gener-
ated subgroup was carried out using the next strongest
associated covariate, and so on. For continuous covari-
ates, clinical meaningful cut-off points were used to
divide the cohort instead of data-driven optimal cut-off
points to avoid overﬁtting.32 For %FEV1, internationally
accepted categories (<40%, 40–69.9% and ≥70%) were
used as these categories are also applicable to the UK
CF registry data.33 Prior-year i.v. days were categorized
into ≤14 days versus >14 days, similar to current-year i.
v. days. The current-year i.v. days, as a continuous vari-
able, were compared between subgroups at each ‘layer’
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of the division using Mann–Whitney test or
Jonckheere–Terpstra test depending on the number of
subgroups, due to the non-normal distribution of i.v.
days. Jonckheere–Terpstra test is a generalization of the
Mann–Whitney test for more than two ordered groups.
The analyses included those without any pulmonary
exacerbations needing i.v. antibiotics (n = 1847, 43.3%
of the sample for 2013; n = 2037, 43.9% of the sample
for 2014) to obtain a more representative understand-
ing of the adult CF population in the UK. P-value <0.05
was considered to be statistically signiﬁcant. Complete
case approach was used as the extent of missing data
(summarized in Fig. 1) was small. There were >1500
people with >14 days i.v. days for each year, which is
more than adequate power for nine covariates in a
binary logistic regression model.34 The study sample
was also considerably larger than previous studies
looking at factors associated with exacerbations18,19
(except the recent US CFFPR analysis), which should
allow adequate power for hypothesis testing between
the different subgroups.
RESULTS
A total of 4269 adults were included in the analysis for
2013 and 4644 for 2014, with 4874 study subjects in
total across both years. In total, 103 453 i.v. days were
used in 2013 and 111 981 i.v. days were used in 2014.
Figure 1 summarizes the numbers of adults excluded
and missing data. Baseline demographics stratiﬁed
according to previous i.v. days was summarized in
Table 1. Those with previous-year i.v. use >14 days had
lower FEV1 and higher current-year i.v. use for both
2013 and 2014.
Graphs displaying the relationships between contin-
uous covariates (age, BMI, %FEV1 and prior-year i.v.
days) with current-year i.v. days are available in
Appendix S1 (Supplementary Information). Contin-
gency tables for all covariates are available in Appendix
S2 (Supplementary Information).
For both 2013 and 2014, prior-year i.v. use was the
strongest predictor for current-year i.v. use, followed by
FEV1. Other covariates such as CF centre and pancre-
atic status were also associated with i.v. use, but the
relationship was weaker and less consistent (Wald sta-
tistic <100) once prior-year i.v. use and FEV1 had been
taken into account (ﬁnal model summarized in
Table 2). Prior-year i.v. use and FEV1 remained the
strongest predictors for current-year i.v. use in various
sensitivity analyses (Appendix S3, Supplementary
Information).
Therefore, the cohort was divided into two groups
based on prior-year i.v. use (≤14 days and >14 days)
Figure 1 Summary of the number of adults included in the analyses and details regarding missing data. †Cystic ﬁbrosis (CF)-related
diabetes (CFRD) data are collected by the UK CF registry with only a check-box for ‘CFRD present’. Therefore, if data are not available,
it is assumed the person has no CFRD. It is therefore difﬁcult to distinguish missing data from ‘no CFRD’ and hence missing data = 0.
‡Data for pancreatic replacement therapy (PERT) use were obtained. People on PERT were considered ‘pancreatic insufﬁcient’. People
not on PERT were considered ‘pancreatic sufﬁcient’. PERT use documented as ‘unknown’ is considered as missing data.
§P. aeruginosa status is collected by the UK CF registry with check-boxes for ‘chronic’ and ‘intermittent’. Therefore, if data are not
available, it is assumed the person has no P. aeruginosa. It is therefore difﬁcult to distinguish missing data from ‘no P. aeruginosa’
and hence missing data = 0.
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and then each group is further divided into three sub-
groups based on %FEV1 (<40%, 40–69.9% and ≥70%) to
generate six subgroups in total. The results of this anal-
ysis are summarized in Figures 2 and 3.
Current-year i.v. use was clearly different between all
the subgroups and the results were consistent for both
2013 and 2014. Adults with high prior-year i.v. use
(i.e. >14 days) continued to require high levels of i.v.,
even if they have good FEV1. Indeed, adults with high
prior-year i.v. use and FEV1 ≥ 70% had higher current-
year i.v. days compared to adults with low prior-year i.
v. use and FEV1 < 40% for both 2013 (28 days, inter-
quartile range (IQR): 11–41 days vs 14 days, IQR:
0–28 days; P < 0.001) and 2014 (22 days, IQR:
10–42 days vs 14 days, IQR: 0–35 days; P = 0.003).
The clinical subgroups could be generated using
different cut-off points for prior-year i.v. use but
the results remained similar (see Appendix S4,
Supplementary Information, for these sensitivity
analyses).
DISCUSSION
This study found that adults with high prior-year i.v.
use (>14 days) and low FEV1 (<40%) required the most
i.v. among the six different clinical subgroups. In 2013,
this group consisted 13.4% of the population but con-
sumed 38.7% of i.v. days. Prior-year i.v. use was a
much stronger predictor of current-year i.v. use com-
pared to FEV1, such that those with high prior-year i.v.
use and high FEV1 (≥70%) still used more i.v. therapies
compared to those with low prior-year i.v. use
(≤14 days) and low FEV1. The 2013 results were con-
sistent with 2014 results, suggesting that chance is
extremely unlikely to explain these results.
The ﬁnding that prior-year i.v. use was the strongest
independent predictor of current-year i.v. use is consist-
ent with the recent US CFFPR analysis.17 Whilst we
acknowledge the limitations of retrospective observa-
tional registry-based analyses that have been previously
discussed,17,35 the consistency and magnitude of the




















Age (years) median (IQR) 28 (22–37) 27 (22–33) 28 (22–35) 28 (22–37) 27 (23–34) 28 (22–36)
Female (%) 995 (40.9) 849 (51.8) 1936 (45.4) 1066 (41.2) 877 (52.4) 2096 (45.1)
Pancreatic insufﬁcient (%) 1858 (77.5) 1487 (92.0) 3449 (82.1) 1967 (77.0) 1526 (91.8) 3756 (81.7)
CF-related diabetes (%) 568 (23.3) 760 (46.3) 1356 (31.8) 620 (24.0) 810 (48.4) 1525 (32.8)
P. aeruginosa status
Chronic P. aeruginosa (%) 1068 (43.9) 1154 (70.4) 2276 (53.3) 1033 (39.9) 1167 (69.7) 2340 (50.4)
Intermittent
P. aeruginosa (%)
350 (14.4) 201 (12.3) 576 (13.5) 422 (16.3) 183 (10.9) 689 (14.8)
BMI in kg/m2, mean (SD) 23.2 (3.9) 21.5 (3.6) 22.6 (3.9) 23.3 (3.9) 21.5 (3.5) 22.6 (3.9)
% predicted FEV1, mean (SD) 73.0 (23.4) 51.8 (21.1) 65.0 (24.8) 73.4 (23.6) 52.7 (21.4) 65.8 (25.0)
Current-year i.v. days,
median (IQR)
0 (0–14) 42 (16–67) 14 (0–35) 0 (0–14) 40 (15–66) 14 (0–34)
†As shown in Figure 1, there were 196 missing data for prior-year i.v. days in 2013.
‡As shown in Figure 1, there were 383 missing data for prior-year i.v. days in 2014.
CF, cystic ﬁbrosis; FEV1, forced expiratory volume in 1 s; IQR, interquartile range.
Table 2 Summary of the output from the ﬁnal binary logistic regression model which include all nine covariates
listed










Prior-year i.v. days 449.5 <0.001 1.06 (1.05–1.06) Prior-year i.v. days 458.1 <0.001 1.06 (1.05–1.06)
% Predicted FEV1 140.1 <0.001 0.97 (0.97–0.98) % Predicted FEV1 172.3 <0.001 0.97 (0.97–0.98)
CF centre 90.3 <0.001 Pancreatic insufﬁcient 32.5 <0.001 2.17 (1.66–2.83)
Pancreatic insufﬁcient 9.6 <0.001 1.59 (1.19–2.13) Female 32.4 <0.001 1.64 (1.38–1.95)
Chronic P. aeruginosa 21.9 <0.001 1.57 (1.30–1.89) Chronic P. aeruginosa 30.9 <0.001 1.78 (1.45–2.18)
Female 15.9 <0.001 1.44 (1.20–1.71) CF centre 67.6 <0.001
Age (years) 17.6 <0.001 0.98 (0.97–0.99) Intermittent
P. aeruginosa
4.2 0.041 1.33 (1.01–1.75)
CF-related diabetes 13.6 <0.001 1.44 (1.19–1.75)
CF, cystic ﬁbrosis; FEV1, forced expiratory volume in 1 s.
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Figure 3 Tree-based diagram for 2014 to summarize current-year i.v. days according to the different clinical subgroups. CF, cystic
ﬁbrosis; FEV1, forced expiratory volume in 1 s; IQR, interquartile range.
Figure 2 Tree-based diagram for 2013 to summarize current-year i.v. days according to the different clinical subgroups. CF, cystic
ﬁbrosis; FEV1, forced expiratory volume in 1 s; IQR, interquartile range.
Respirology (2017) © 2017 The Authors
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ﬁnding would suggest a genuine signal. The implica-
tions of this ﬁnding for clinical trials had also been dis-
cussed in detail—stratiﬁcation of subject randomization
by prior-year i.v. use would be helpful to balance the
baseline risk of pulmonary exacerbation. In fact, our
randomized control trial to evaluate a complex self-care
intervention used this strategy for randomization.36
This ﬁnding also has other important clinical implica-
tions and could suggest possible differences in manage-
ment strategies. Management of CF can be broadly
dichotomized into ‘rescue’ therapy with i.v. antibiotics
to treat pulmonary exacerbations and ‘prevention’ with
inhaled therapies to minimize the risk of exacerba-
tions.37 Whilst exacerbations may be stochastic events,
the frequency and severity of exacerbations over a given
period in a person with CF will be inﬂuenced by their
clinical characteristics, environmental exposures and
medical treatments.38 Given the efﬁcacy of preventative
inhaled therapies in reducing the frequency of
exacerbations,5,6 a possible explanation for high i.v. use
would be the reliance on rescue therapies to compen-
sate for insufﬁcient utilization of preventative therapies.
Prior-year i.v. use could also guide clinical strategy
in managing CF. Insufﬁcient utilization of preventative
therapy could be due to low adherence, as median
adherence with inhaled therapies in the real world is
only 35–50%.7,8,39 Therefore, it is important to obtain
objective adherence data wherever possible when
assessing an adult with CF, especially if i.v. use is dis-
proportionately high in relation to FEV1.
If objective nebulizer adherence is satisfactory,
another cause for insufﬁcient utilization of preventative
therapy to consider is ‘therapeutic inertia’. Therapeutic
inertia refers to the under-prescription of efﬁcacious
treatments.40 In CF, the prescription of inhaled thera-
pies have increased since mid 1990s.41–43 Adherence
rates to international prescribing guidelines now
exceed 90% for some specialist CF centres.44 If i.v.
requirement is still disproportionately high but objec-
tive adherence is high and no obvious complications
are found, escalation of preventative therapies should
be considered. An example would be the initiation of
inhaled antibiotic treatment for someone who is only
on inhaled mucolytics. The detection of P. aeruginosa
infection would typically prompt the prescription of
inhaled antibiotics. However, there may be merit in
using long-term inhaled antibiotics, even when
P. aeruginosa is not detected, if there is a history of fre-
quent exacerbations.45 This is a strategy that has some
evidence of success in non-CF bronchiectasis.46
Our ﬁnding highlights potential limitations of FEV1
as a marker of lung health. Low FEV1 is a known poor
prognostic marker in CF and is strongly associated with
mortality.47,48 FEV1 trend is therefore a commonly used
primary end point in CF clinical trials and an important
parameter measured during annual reviews as a
marker of lung health for adults with CF.16,49 However,
as the health of people with CF improved over time,
the sensitivity of FEV1 as a marker of lung health
decreases.50 This study found a group of people with
high i.v. use year on year, yet who maintained rela-
tively good lung function (FEV1 > 70%). It may be pos-
sible to initially fend off FEV1 decline despite frequent
exacerbations by simply relying on prompt and
aggressive rescue i.v. treatments. Such strategy is likely
to result in wild ﬂuctuations of FEV1, with high FEV1
post i.v. treatment not sustained due to lack of preven-
tative treatments. A trend of declining FEV1 tends to be
predated by increased FEV1 variability
51; hence, FEV1
variability is a more sensitive marker of lung health.
There is increasing evidence regarding the prognostic
impact of FEV1 variability,
51,52 but we were not able to
study the correlation between FEV1 variability and i.v.
use as the UK CF registry does not routinely collect
encounter-based FEV1 data.
In conclusion, exacerbations as indicated by i.v. use
are clinically important events in CF with long-term
impact on morbidity and mortality. Prevention of
exacerbations is a priority due to the risk of FEV1
decline and lung damage even with intensive i.v. anti-
biotics, hence the importance of understanding the
predictors of frequent exacerbations. This UK CF regis-
try analysis used i.v. days as a marker of the frequency
and severity of exacerbations, and found that current-
year i.v. use is most strongly associated with prior-year
i.v. use. A recent US CFFPR data analysis also found
similar results.17 That means those with history of fre-
quent exacerbations continue to remain most at risk
for future exacerbations, even with good FEV1. Inade-
quate utilization of preventative inhaled therapies may
be one of the reasons for this reliance on rescue thera-
pies. Therefore, high i.v. use should prompt clinicians
to assess both the adherence rate and the prescribed
inhaled therapies regime.
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